Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

NCT01254864 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

190

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Abiraterone Acetate
DRUG: Prednisone
DRUG: Sunitinib
DRUG: Dasatinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]